登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07560488,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Normal thyroid function defined as thyroid-stimulating hormone (TSH) within normal limits. Subjects with abnormal baseline TSH but normal total T3 (or FT3) and FT4 are also eligible;
入选标准第 17 条
Symptomatic congestive heart failure (NYHA Class II-IV); symptomatic or poorly controlled arrhythmia; congenital long QT syndrome or QTcF >500 ms at screening;
排除标准第 16 条
All subjects (male or female) of reproductive potential must use a highly effective contraceptive method with an annual failure rate < 1% throughout treatment and for 120 days after the last dose of immunotherapy or 180 days after the last dose of chemotherapy, whichever is longer.
入选标准第 20 条
Prior treatment with anti-PD-1, anti-PD-L1/L2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors;
排除标准第 30 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
入选标准第 7 条
Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L without granulocyte colony-stimulating factor support within 14 days;
入选标准第 10 条
Platelet count ≥ 80×10⁹/L without transfusion within 14 days;
入选标准第 11 条
Hemoglobin > 9 g/dL without transfusion or erythropoietin within 14 days;
入选标准第 12 条
Total bilirubin ≤ 1.5×upper limit of normal (ULN); or total bilirubin > ULN with direct bilirubin ≤ ULN;
入选标准第 13 条
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3×ULN;
入选标准第 14 条
Serum creatinine ≤ 1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥ 60 mL/min;
入选标准第 15 条
Autoimmune hepatitis (requiring liver biopsy confirmation);
排除标准第 5 条
Acute or chronic active hepatitis B or C infection:HBV DNA >2000 IU/mL or 10⁴ copies/mL;HCV RNA >10³ copies/mL;coinfection with HBsAg and anti-HCV antibody;
排除标准第 20 条
Active tuberculosis (TB), ongoing anti-TB treatment, or anti-TB treatment within 1 year before first dose;
排除标准第 21 条
Human immunodeficiency virus (HIV) infection (positive HIV 1/2 antibody) or active syphilis;
排除标准第 22 条
Diagnosis of another malignancy within 5 years before first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ.For other malignancies diagnosed >5 years before enrollment, pathological or cytological confirmation of recurrent/metastatic lesions is required;
排除标准第 29 条
Female subjects who are pregnant or breastfeeding;
排除标准第 33 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07560488,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Written informed consent must be signed prior to initiation of any study-related procedures; Age ≥ 18 years, and ≤75 years, regardless of gender; Clinically diagnosed or histologically/cytologically confirmed hepatocellular carcinoma (HCC) according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition); No prior anti-tumor therapy for HCC before study treatment Unresectable locally advanced or advanced HCC (CNLC Stage IIa-IIIb). Expected overall survival > 6 months. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Child-Pugh score class A or B Adequate organ function defined by the following laboratory parameters: Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L without granulocyte colony-stimulating factor support within 14 days; Platelet count ≥ 80×10⁹/L without transfusion within 14 days; Hemoglobin > 9 g/dL without transfusion or erythropoietin within 14 days; Total bilirubin ≤ 1.5×upper limit of normal (ULN); or total bilirubin > ULN with direct bilirubin ≤ ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3×ULN; Serum creatinine ≤ 1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥ 60 mL/min; Adequate coagulation function defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5×ULN; Normal thyroid function defined as thyroid-stimulating hormone (TSH) within normal limits. Subjects with abnormal baseline TSH but normal total T3 (or FT3) and FT4 are also eligible; Myocardial enzymes within normal limits; isolated laboratory abnormalities deemed clinically insignificant by the investigator are permitted. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose of study drug (Day 1 of Cycle 1). A blood pregnancy test is required if the urine test is inconclusive; They must agree to use adequate contraception during the study period and for 8 weeks after the last dose of study drug; All subjects (male or female) of reproductive potential must use a highly effective contraceptive method with an annual failure rate < 1% throughout treatment and for 120 days after the last dose of immunotherapy or 180 days after the last dose of chemotherapy, whichever is longer.排除标准:Exclusion Criteria:
Target disease exceptions: Fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma. Recurrent HCC. Clinically diagnosed hepatic encephalopathy within the most recent 6 months. Autoimmune hepatitis (requiring liver biopsy confirmation); History of organ transplantation or history of hepatic encephalopathy; Diffuse hepatocellular carcinoma; Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage; History of any renal disease or nephrotic syndrome. Variceal bleeding (esophageal or gastric varices) due to portal hypertension within the past 6 months;severe (Grade 3) varices on endoscopy within 3 months before first dose;evidence of portal hypertension (e.g., splenomegaly >10 cm in longest diameter with platelets <100×10⁹/L on imaging) with high bleeding risk as assessed by the investigator; Arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other severe thromboembolism.Excluded are catheter-related or port-related thrombosis or superficial venous thrombosis that is stable with standard anticoagulation; Severe bleeding tendency or coagulopathy, or ongoing thrombolytic therapy; Prophylactic low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) is permitted; vitamin K antagonists (e.g., warfarin) are excluded; Long-term use of anti-platelet agents including aspirin, dipyridamole, clopidogrel, or other similar medications; Uncontrolled hypertension despite optimal medical management (systolic BP >140 mmHg or diastolic BP >90 mmHg); history of hypertensive crisis or hypertensive encephalopathy; Symptomatic congestive heart failure (NYHA Class II-IV); symptomatic or poorly controlled arrhythmia; congenital long QT syndrome or QTcF >500 ms at screening; History of gastrointestinal perforation and/or fistula within the past 6 months; history of bowel obstruction (including partial obstruction requiring parenteral nutrition); extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea; Major surgical procedure (cranial, thoracic, or abdominal) within 4 weeks before first dose, or non-healing wounds, ulcers, or fractures.Core needle biopsy or minor surgery within 7 days before first dose is excluded, except for venous catheter placement for intravenous access; History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonitis, or severe pulmonary dysfunction; Acute or chronic active hepatitis B or C infection:HBV DNA >2000 IU/mL or 10⁴ copies/mL;HCV RNA >10³ copies/mL;coinfection with HBsAg and anti-HCV antibody; Active tuberculosis (TB), ongoing anti-TB treatment, or anti-TB treatment within 1 year before first dose; Human immunodeficiency virus (HIV) infection (positive HIV 1/2 antibody) or active syphilis; Active or poorly controlled severe infection; severe infection requiring hospitalization (including sepsis, bacteremia, or severe pneumonia) within 4 weeks before first dose; Active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years before first dose.Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal/pituitary insufficiency) is permitted.History of primary immunodeficiency.Subjects with isolated positive autoimmune antibodies will be evaluated at the investigator's discretion; Systemic immunosuppressive drugs within 4 weeks before first dose, excluding topical, inhaled, or intranasal corticosteroids or physiological systemic corticosteroids (≤10 mg/day prednisone or equivalent).Temporary corticosteroids for acute dyspnea in asthma or COPD are permitted; Live attenuated vaccine within 4 weeks before first dose or planned use during the study period; Chinese herbal medicine with anti-tumor indications, or immunomodulatory agents (including thymosin, interferon, interleukin) within 2 weeks before first dose, except for local administration for pleural effusion or ascites; Uncontrolled or irreversible metabolic disorders, other acute or chronic non-malignant organ diseases, systemic illnesses, or paraneoplastic syndromes that may increase medical risk or confound survival assessment; Diagnosis of another malignancy within 5 years before first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ.For other malignancies diagnosed >5 years before enrollment, pathological or cytological confirmation of recurrent/metastatic lesions is required; Prior treatment with anti-PD-1, anti-PD-L1/L2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors; Known hypersensitivity to sintilimab, bevacizumab, ipilimumab N01 or their excipients, or severe hypersensitivity to other monoclonal antibodies; Participation in another interventional clinical trial within 4 weeks before first dose; Female subjects who are pregnant or breastfeeding; Any other acute or chronic diseases, psychiatric disorders, or abnormal laboratory values that may increase risks associated with study participation or study drug administration, or interfere with the interpretation of study results, and that, in the investigator's judgment, render the patient ineligible for participation in this study.
引自 ClinicalTrials.gov, NCT07560488, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07560488,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。